WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 15-Jul-2018 (data as of 15-Jul-2018)
Next overall update Winter 2018
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 80'5601 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 65'0071 Child (under 5 years) mortality rate: 42

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 8'476  8'402  8'320  8'230  8'133  7'167  6'675  6'304 
Births 88  87  86  85  84  76  81  73 
Surviving infants 88  87  86  85  84  76  80  72 
Pop. less than 5 years 440  434  427  420  412  401  385  356 
Pop. less than 15 years 1'261  1'246  1'230  1'216  1'203  1'251  1'138  1'261 
Female 15-49 years 1'930  1'939  1'945  1'942  1'935  1'766  1'719  1'587 

Number of reported cases

(Click for retrospective incidence data for Switzerland)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  105  65  35  23  175  1'990 
Mumps
ChartChart
 
Pertussis
ChartChart
  8'740  8'046 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Switzerland)
Vaccine year result method % card seen                                                
BCG         
DTP1          98  95 
DTP3          97  96  96  96  96  93  90 
DTP4          87  89  91  89 
IPV1          97 
HepB_BD         
HepB3          65  17  17  16 
Hib3          95  95  95  95  95  91 
JapEnc         
MCV1          95  94  94  94  93  82  90 
MCV2          89  87  87  87  86 
MenA         
PCV1          86  85  85  84 
PCV2          85  84  85  83 
PCV3          83  80  80  80  75 
Pol3          96  96  96  96  96  95  98 
Rota1         
RotaC         
RCV1          95  93  94  93 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2019

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Switzerland)
DTP1
ChartChart
  98  98  97  97  96  95  96 
DTP3
ChartChart
  97  96  96  96  96  93  90 
HepB3
 
HepB_BD
 
Hib3
ChartChart
  95  95  95  95  95  91 
MCV1
ChartChart
  95  94  94  94  93  82  90 
MCV2
ChartChart
  89  87  87  87  86 
PCV3
ChartChart
  83  80  80  80  75 
Pol3
  96  96  96  96  96  95  98 
RCV1
ChartChart
  95  94  94  94  93  82  90 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 26  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 27
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
73
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepBIPV 2, 4, 6, 15-24 months; Yes
DTaPHibHepIPV 2, 4, 6, 15-24 months; Yes
DTaPHibIPV 2, 4, 6, 15-24 months; Yes
DTaPIPV 4-7 years; Yes
HepA_Adult risk groups
HepA_Pediatric Yes risk groups
HepB_Adult 11-15 years; +6 months; Yes and risk groups
HepB_Pediatric birth; 1, 6, 15-24 months; Yes infant exposed to the HBV by the mother
HIB 2, 4, 6, 15-24 months; Yes infants of parents who would like immunised only against Hib
HPV 11-14 years; +6 months; Yes catchup 15-19 years: 3 doses; supplementary 20-26 years
Influenza_Adult >=65 years; Yes and adults with chronic illness, pregnant women, health care workers, residents living in long-term care facilities
Influenza_Pediatric Yes children with chronic illness
MenACWY-135 conj Yes risk groups, prophylaxe post-expositionnel
MenC_conj 12 months; 11-15 years; Yes supplementary; and risk groups, supplementary
MMR 12, 15-24 months; Yes
Pneumo_conj 2, 4, 12 months; Yes or 2, 4, 6, 12 months for risk groups
Td 45, 65 years; Yes and every 10 years thereafter
Tdap 11-15, 25-29 years; Yes pregnant women and person in contact with infants < 6 months
TdaPIPV 11-15 years; Yes in case of catchup/booster polio immunization is needed, and immunisation against pertussis (like pregnancy)
TdIPV Yes in case of catchup polio immunization in the same time as tetanus and diphtheria
Typhoid Yes travellers under some conditions
Varicella 11-15 years; Yes no anamnestic disease and for risk groups from age of 1 years
YF Yes travellers according to WHO recommendations

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  No  Yes  Yes  Yes 
What years does the MYP cover? number         2012-2015  2012-2015   
Nº of districts with microplans that include activities to raise immunization coverage number          

System performance

Total Nº districts in country number 26  26  26  26      26 
Nº districts with DTP3 coverage >=80% number        
% of districts with DTP3 coverage >=80% From 0 to 100% 27             
Nº districts with measles (MCV1) coverage >=95% number        
% of districts with MCV1 coverage >=95% From 0 to 100% 12             

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes    Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%        

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2018 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2018, data for 2016
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.